AC4 Stock Overview
Operates as a cannabis company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Australis Capital Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0085 |
| 52 Week High | CA$0.092 |
| 52 Week Low | CA$0.005 |
| Beta | 1.13 |
| 11 Month Change | 0% |
| 3 Month Change | 70.00% |
| 1 Year Change | -90.34% |
| 33 Year Change | -97.09% |
| 5 Year Change | n/a |
| Change since IPO | -98.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| AC4 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -5.0% | -1.3% |
| 1Y | -90.3% | -22.0% | 7.4% |
Return vs Industry: AC4 underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: AC4 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| AC4 volatility | |
|---|---|
| AC4 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AC4's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine AC4's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Terry Booth | www.ausacap.com |
Australis Capital Inc. operates as a cannabis company. It undertakes cannabis and non-cannabis, as well as horticulture projects in the United States, Canada, Denmark Finland, Iceland, Germany, the Netherlands, Bahrein, Kuwait, Southeast Asia, and Australia, as well as other jurisdictions. The company is headquartered in Las Vegas, Nevada.
Australis Capital Inc. Fundamentals Summary
| AC4 fundamental statistics | |
|---|---|
| Market cap | €6.03m |
| Earnings (TTM) | -€34.52m |
| Revenue (TTM) | €6.53m |
0.9x
P/S Ratio-0.2x
P/E RatioIs AC4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AC4 income statement (TTM) | |
|---|---|
| Revenue | CA$9.47m |
| Cost of Revenue | CA$3.61m |
| Gross Profit | CA$5.87m |
| Other Expenses | CA$55.96m |
| Earnings | -CA$50.09m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 61.95% |
| Net Profit Margin | -528.67% |
| Debt/Equity Ratio | 5.4% |
How did AC4 perform over the long term?
See historical performance and comparison